Contacts

Pere Domingo, MD, PhD

CONTACT

[email protected]

Sponsors

Lead Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Collaborators

Instituto de Salud Carlos III

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Subject (or authorized legal representative) who can provide written informed consent before beginning any study procedure.
•Understand and agree to abide by the study procedures.
•Adult #18 years of age at the time of inclusion in the study.
•Confirmation of SARS-CoV-2 infection by a microbiological test performed before randomization, no longer than 72 hours.
•Severity 3-4 according to the WHO 7-point ordinal scale.

Exclusion Criteria

•ALT / AST\> 5 times the normal limit
•Stage 4 chronic kidney disease (GFR \<30) or requiring dialysis.
•Presence of comorbidities that imply a poor prognosis (according to clinical judgment).
•Advanced dementia.
•Pregnancy or breastfeeding.
•Anticipation of transfer to another center in the 12 hours at the beginning of the study.
•Allergy to study medication.
•Serious or active bacterial infections or documented sepsis by pathogens other than SARS-CoV-2.
•Streptococcus pneumoniae antigenuria positive before study start.
•Neutropenia \<500 / mm3.
•Thrombocytopenia \<100,000 / mm3.
•History of diverticulosis.
•Ongoing skin infection (eg, pyodermitis).
•Transplanted patient under immunosuppressive treatment.
•Previous evidence of latent untreated tuberculosis.

Related studies

RECRUITINGPhase 3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287 · Long COVID, Sars-CoV-2 Infection, and more

RECRUITINGPhase 1

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

NCT05101213 · Adenovirus Infection, BK Virus Infection, and more

RECRUITINGPhase 1/2

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT04565665 · COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, and more

RECRUITINGNA

Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19

NCT06871293 · Long COVID-19 Syndrome, COVID 19, and more

RECRUITINGNA

Long COVID Brain Fog: Cognitive Rehabilitation Trial

NCT06095297 · Long COVID, Brain Fog, and more

View all related studies →

Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19

Long COVID Brain Fog: Cognitive Rehabilitation Trial

Trial snapshot

Condition

Locations shown

For caregivers